[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Sanofi-Aventis S.A. ADR (SNY)

Sanofi-Aventis S.A. ADR (SNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Sanofi: The Estimate Everyone Agrees On Rarely Survives Contact With July

Sanofi (SNY) reports Q2 2026 earnings tomorrow, July 30, before market open, with analysts expecting EPS of $1.10 on the heels of three consecutive earnings beats. The French pharmaceutical giant faces a critical test as investors weigh its recent momentum against a deteriorating analyst sentiment backdrop and technical signals that have weakened sharply over the past month.

Sanofi is a global biopharmaceutical company focused on human health, with operations spanning prescription pharmaceuticals, vaccines, and consumer healthcare products across multiple therapeutic areas including immunology, oncology, and rare diseases. The company's diversified portfolio and strong presence in both developed and emerging markets make it a...

Fundamentals

See More
  • Market Capitalization, $K 108,735,456
  • Shares Outstanding, K 2,424,425
  • Annual Sales, $ 52,854 M
  • Annual Income, $ 8,840 M
  • EBIT $ 12,044 M
  • EBITDA $ 18,468 M
  • 60-Month Beta 0.34
  • Price/Sales 2.24
  • Price/Cash Flow 6.23
  • Price/Book 1.25

Options Overview Details

View History
  • Implied Volatility 27.87% (-1.59%)
  • Historical Volatility 26.96%
  • IV Percentile 62%
  • IV Rank 40.87%
  • IV High 37.73% on 04/13/26
  • IV Low 21.06% on 05/21/26
  • Expected Move (DTE 22) 2.54 (5.67%)
  • Put/Call Vol Ratio 1.59
  • Today's Volume 8,629
  • Volume Avg (30-Day) 2,699
  • Put/Call OI Ratio 0.99
  • Today's Open Interest 78,039
  • Open Int (30-Day) 76,462
  • Expected Range 42.31 to 47.39

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $1.10
  • Number of Estimates 4
  • High Estimate $1.14
  • Low Estimate $1.02
  • Prior Year $0.90
  • Growth Rate Est. (year over year) +22.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
41.27 +8.67%
on 07/01/26
45.67 -1.78%
on 07/29/26
+1.42 (+3.27%)
since 06/29/26
3-Month
40.89 +9.68%
on 06/22/26
46.98 -4.53%
on 05/01/26
-1.18 (-2.56%)
since 04/29/26
52-Week
40.89 +9.68%
on 06/22/26
52.68 -14.86%
on 11/13/25
-4.50 (-9.12%)
since 07/29/25

Most Recent Stories

More News
Sanofi: The Estimate Everyone Agrees On Rarely Survives Contact With July

Barchart Research What to Expect from SNY Earnings SNY Generated July 29, 2026 Current Price $44.85 EPS Estimate $$1.10 Consensus Rating Moderate Buy Average Move 3.35% Sanofi: The Estimate Everyone Agrees...

SNY : 44.85 (-1.52%)
Next-Generation Diabetes Therapies Are Reshaping Healthcare and Creating MultiBillion-Dollar Revenue Opportunities

EQNX::TICKER_START (OTCQB:AVAI),(NYSE:NVO),(NASDAQ:SNY),(NASDAQ:DXCM),(NASDAQ:TNDM) EQNX::TICKER_END

AVAI : 0.1300 (-16.13%)
TNDM : 18.59 (+4.67%)
NVO : 51.58 (+1.22%)
DXCM : 75.14 (+0.39%)
SNY : 44.85 (-1.52%)
1 of the Most Interesting AI Stocks in the Market Isn’t a Tech Company

Recursion Pharmaceuticals is trying to prove that AI’s next big winner can also come from biotech, and not just from the tech sector.

RXRX : 2.97 (-2.62%)
RHHBY : 54.9700 (-2.74%)
SNY : 44.85 (-1.52%)
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.

QNTM : 2.83 (-5.67%)
QNTM.CN : 4.0000 (-4.31%)
CLNN : 4.72 (-5.41%)
RHHBY : 54.9700 (-2.74%)
SNY : 44.85 (-1.52%)
BIIB : 209.23 (+1.76%)
The $11 Billion Reason Abbvie Stock Is Up Today

AbbVie stock rallied today on the $10.9 billion acquisition of Apogee Therapeutics. Here’s how you should play ABBV shares at current levels.

APGE : 134.20 (+0.02%)
JNJ : 265.53 (-0.45%)
LLY : 1,210.02 (-0.87%)
ABBV : 263.30 (+0.04%)
REGN : 695.42 (+0.03%)
SNY : 44.85 (-1.52%)
Regeneron Sinks 10% on Failed Phase 3 Melanoma Trial. What Comes Next for REGN Stock.

Regeneron stock sinks as fianlimab Phase 3 trial fails to meet primary endpoint. But RBC continues to see significant upside in REGN shares from here.

MRK : 130.36 (-1.11%)
REGN : 695.42 (+0.03%)
SNY : 44.85 (-1.52%)
Sanofi Supports AlphaDetect to Accelerate Detection of Alpha-1

The sponsorship helps expand proven Alpha-1 detection strategies, which will enable earlier patient identification

SAN : 13.38 (-4.29%)
SNY : 44.85 (-1.52%)
Giants Costco, Sanofi, and SAP Raise Dividends by Over 10%

Dividends are on the rise at Costco, Sanofi, and SAP, three of the world's largest companies with market capitalizations above $100 billion.

COST : 974.03 (+0.77%)
SAP : 185.99 (+3.81%)
WMT : 114.22 (+0.99%)
SNY : 44.85 (-1.52%)
Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)

Approval for children aged 2 to 11 years with CSU who remain symptomatic despite H1 antihistamine treatment based primarily on data from the LIBERTY-CUPID clinical trial program CSU is a chronic skin...

SAN.FP : 75.990 (-4.92%)
REGN : 695.42 (+0.03%)
SNY : 44.85 (-1.52%)
Sanofi's Pipeline Downgrades Suggest Thursday's Beat Won't Matter

Barchart Research What to Expect from SNY Earnings SNY Generated April 22, 2026 Current Price $46.90 EPS Estimate $$1.06 Consensus Rating Moderate Buy Average Move 3.92% Sanofi's Pipeline Downgrades Suggest...

SNY : 44.85 (-1.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme,...

See More

Key Turning Points

3rd Resistance Point 46.29
2nd Resistance Point 45.98
1st Resistance Point 45.41
Last Price 44.85
1st Support Level 44.54
2nd Support Level 44.23
3rd Support Level 43.66

See More

52-Week High 52.68
Fibonacci 61.8% 48.18
Fibonacci 50% 46.78
Fibonacci 38.2% 45.39
Last Price 44.85
52-Week Low 40.89

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.